REGENERON PHARMACEUTICALS, INC. (REGN) Cash flow statement
Top 10 of 23 line items reported by REGN · 250+ in the full API →
REGENERON PHARMACEUTICALS, INC. (REGN) · Cash Flow Statement
Consolidated Statements of Cash Flows
Quarterly · In millions USD, except per-share data · Latest filed Oct 30, 2026 · FY ends Dec 31
| Three Months Ended | ||||||
|---|---|---|---|---|---|---|
Q3 2026 Sep 30, 2026 | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Trend | |
| Net Cash Flow from Operating Activities | $1,783.4 | $813 | $1,078.9 | $1,170.7 | $1,618.7 | |
| Net Income | 1,948.7 | 1,296.9 | 727.2 | 844.6 | 1,460 | |
| Net Cash Flow from Investing Activities | $(288.1) | $(92.7) | $(428.9) | $220.3 | $(402.9) | |
| Capital Expenditures | -300.2 | -240.2 | -230.6 | -248.7 | -201.4 | |
| Net Cash Flow from Financing Activities | $(290.2) | $(1,224.6) | $(802.2) | $(780.1) | $(717.9) | |
| Common stock issued | 300.9 | 49.2 | 163.1 | 503.5 | 40.3 | |
| Common stock repurchased | -399.7 | -1,169.4 | -794.3 | -671.7 | -664 | |
| Other financing activities | 0 | 0 | 0 | 0 | 0 | |
| Net Cash Flow | $1,205.6 | $(504.6) | $(153.1) | $610.6 | $497.5 | |
| Free Cash Flow | 1,483.2 | 572.8 | 848.3 | 922 | 1,417.3 | |
Quarterly figures are derived from year-to-date filed amounts.
13 more line items available via the API
Depreciation & AmortizationStock-Based CompensationAccounts receivableInventoriesOther current assetsAccounts payableNet Debt Issued (Repaid)Total debt issuedShort-term debt issuedLong-term debt issuedTotal debt repaidShort-term debt repaidLong-term debt repaid